Unresectable Hepatocellular Carcinoma Treatment Market, Global Outlook and Forecast 2022-2028

July 2022 | 67 pages | ID: U7D9CA0EE373EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Unresectable Hepatocellular Carcinoma Treatment in Global, including the following market information:

Global Unresectable Hepatocellular Carcinoma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Unresectable Hepatocellular Carcinoma Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Novel T Cell Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Unresectable Hepatocellular Carcinoma Treatment include Pfizer Inc., Eli Lilly, Bayer AG, Merck & Co. Inc., Bristol-Myers-Squibb Company, Celgene Corporation, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd and Chugai Pharmaceutical Co. Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Unresectable Hepatocellular Carcinoma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Unresectable Hepatocellular Carcinoma Treatment Market, by Treatment Method, 2017-2022, 2023-2028 ($ millions)

Global Unresectable Hepatocellular Carcinoma Treatment Market Segment Percentages, by Treatment Method, 2021 (%)

• Novel T Cell Therapy
• Chemotherapy

Global Unresectable Hepatocellular Carcinoma Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Unresectable Hepatocellular Carcinoma Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Others

Global Unresectable Hepatocellular Carcinoma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Unresectable Hepatocellular Carcinoma Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Unresectable Hepatocellular Carcinoma Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Unresectable Hepatocellular Carcinoma Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer Inc.
• Eli Lilly
• Bayer AG
• Merck & Co. Inc.
• Bristol-Myers-Squibb Company
• Celgene Corporation
• Eisai Co. Ltd
• F. Hoffmann-La Roche Ltd
• Chugai Pharmaceutical Co. Ltd
• Pharmaxis
• BeiGene
• Astrazeneca PLC

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Unresectable Hepatocellular Carcinoma Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Treatment Method
  1.2.2 Market by Application
1.3 Global Unresectable Hepatocellular Carcinoma Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA TREATMENT OVERALL MARKET SIZE

2.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Size: 2021 VS 2028
2.2 Global Unresectable Hepatocellular Carcinoma Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Unresectable Hepatocellular Carcinoma Treatment Players in Global Market
3.2 Top Global Unresectable Hepatocellular Carcinoma Treatment Companies Ranked by Revenue
3.3 Global Unresectable Hepatocellular Carcinoma Treatment Revenue by Companies
3.4 Top 3 and Top 5 Unresectable Hepatocellular Carcinoma Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Unresectable Hepatocellular Carcinoma Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Unresectable Hepatocellular Carcinoma Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Unresectable Hepatocellular Carcinoma Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Unresectable Hepatocellular Carcinoma Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Treatment Method - Global Unresectable Hepatocellular Carcinoma Treatment Market Size Markets, 2021 & 2028
  4.1.2 Novel T Cell Therapy
  4.1.3 Chemotherapy
4.2 By Treatment Method - Global Unresectable Hepatocellular Carcinoma Treatment Revenue & Forecasts
  4.2.1 By Treatment Method - Global Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2022
  4.2.2 By Treatment Method - Global Unresectable Hepatocellular Carcinoma Treatment Revenue, 2023-2028
  4.2.3 By Treatment Method - Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Unresectable Hepatocellular Carcinoma Treatment Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Others
5.2 By Application - Global Unresectable Hepatocellular Carcinoma Treatment Revenue & Forecasts
  5.2.1 By Application - Global Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Unresectable Hepatocellular Carcinoma Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Unresectable Hepatocellular Carcinoma Treatment Market Size, 2021 & 2028
6.2 By Region - Global Unresectable Hepatocellular Carcinoma Treatment Revenue & Forecasts
  6.2.1 By Region - Global Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Unresectable Hepatocellular Carcinoma Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2028
  6.3.2 US Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.3.3 Canada Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.3.4 Mexico Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2028
  6.4.2 Germany Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.4.3 France Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.4.4 U.K. Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.4.5 Italy Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.4.6 Russia Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.4.8 Benelux Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2028
  6.5.2 China Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.5.3 Japan Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.5.4 South Korea Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.5.6 India Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2028
  6.6.2 Brazil Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.6.3 Argentina Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2028
  6.7.2 Turkey Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.7.3 Israel Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028
  6.7.5 UAE Unresectable Hepatocellular Carcinoma Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer Inc.
  7.1.1 Pfizer Inc. Corporate Summary
  7.1.2 Pfizer Inc. Business Overview
  7.1.3 Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.1.4 Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Inc. Key News
7.2 Eli Lilly
  7.2.1 Eli Lilly Corporate Summary
  7.2.2 Eli Lilly Business Overview
  7.2.3 Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.2.4 Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.2.5 Eli Lilly Key News
7.3 Bayer AG
  7.3.1 Bayer AG Corporate Summary
  7.3.2 Bayer AG Business Overview
  7.3.3 Bayer AG Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.3.4 Bayer AG Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.3.5 Bayer AG Key News
7.4 Merck & Co. Inc.
  7.4.1 Merck & Co. Inc. Corporate Summary
  7.4.2 Merck & Co. Inc. Business Overview
  7.4.3 Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.4.4 Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.4.5 Merck & Co. Inc. Key News
7.5 Bristol-Myers-Squibb Company
  7.5.1 Bristol-Myers-Squibb Company Corporate Summary
  7.5.2 Bristol-Myers-Squibb Company Business Overview
  7.5.3 Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.5.4 Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.5.5 Bristol-Myers-Squibb Company Key News
7.6 Celgene Corporation
  7.6.1 Celgene Corporation Corporate Summary
  7.6.2 Celgene Corporation Business Overview
  7.6.3 Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.6.4 Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.6.5 Celgene Corporation Key News
7.7 Eisai Co. Ltd
  7.7.1 Eisai Co. Ltd Corporate Summary
  7.7.2 Eisai Co. Ltd Business Overview
  7.7.3 Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.7.4 Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.7.5 Eisai Co. Ltd Key News
7.8 F. Hoffmann-La Roche Ltd
  7.8.1 F. Hoffmann-La Roche Ltd Corporate Summary
  7.8.2 F. Hoffmann-La Roche Ltd Business Overview
  7.8.3 F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.8.4 F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.8.5 F. Hoffmann-La Roche Ltd Key News
7.9 Chugai Pharmaceutical Co. Ltd
  7.9.1 Chugai Pharmaceutical Co. Ltd Corporate Summary
  7.9.2 Chugai Pharmaceutical Co. Ltd Business Overview
  7.9.3 Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.9.4 Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.9.5 Chugai Pharmaceutical Co. Ltd Key News
7.10 Pharmaxis
  7.10.1 Pharmaxis Corporate Summary
  7.10.2 Pharmaxis Business Overview
  7.10.3 Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.10.4 Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.10.5 Pharmaxis Key News
7.11 BeiGene
  7.11.1 BeiGene Corporate Summary
  7.11.2 BeiGene Business Overview
  7.11.3 BeiGene Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.11.4 BeiGene Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.11.5 BeiGene Key News
7.12 Astrazeneca PLC
  7.12.1 Astrazeneca PLC Corporate Summary
  7.12.2 Astrazeneca PLC Business Overview
  7.12.3 Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Major Product Offerings
  7.12.4 Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Revenue in Global Market (2017-2022)
  7.12.5 Astrazeneca PLC Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Unresectable Hepatocellular Carcinoma Treatment Market Opportunities & Trends in Global Market
Table 2. Unresectable Hepatocellular Carcinoma Treatment Market Drivers in Global Market
Table 3. Unresectable Hepatocellular Carcinoma Treatment Market Restraints in Global Market
Table 4. Key Players of Unresectable Hepatocellular Carcinoma Treatment in Global Market
Table 5. Top Unresectable Hepatocellular Carcinoma Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Unresectable Hepatocellular Carcinoma Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Unresectable Hepatocellular Carcinoma Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Unresectable Hepatocellular Carcinoma Treatment Product Type
Table 9. List of Global Tier 1 Unresectable Hepatocellular Carcinoma Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Unresectable Hepatocellular Carcinoma Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Treatment Method – Global Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Treatment Method - Unresectable Hepatocellular Carcinoma Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Treatment Method - Unresectable Hepatocellular Carcinoma Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Unresectable Hepatocellular Carcinoma Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Unresectable Hepatocellular Carcinoma Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Inc. Corporate Summary
Table 31. Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 32. Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Eli Lilly Corporate Summary
Table 34. Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 35. Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Bayer AG Corporate Summary
Table 37. Bayer AG Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 38. Bayer AG Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Merck & Co. Inc. Corporate Summary
Table 40. Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 41. Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers-Squibb Company Corporate Summary
Table 43. Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 44. Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Celgene Corporation Corporate Summary
Table 46. Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 47. Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Eisai Co. Ltd Corporate Summary
Table 49. Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 50. Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 51. F. Hoffmann-La Roche Ltd Corporate Summary
Table 52. F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 53. F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Chugai Pharmaceutical Co. Ltd Corporate Summary
Table 55. Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 56. Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Pharmaxis Corporate Summary
Table 58. Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 59. Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 60. BeiGene Corporate Summary
Table 61. BeiGene Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 62. BeiGene Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Astrazeneca PLC Corporate Summary
Table 64. Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Product Offerings
Table 65. Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Unresectable Hepatocellular Carcinoma Treatment Segment by Treatment Method in 2021
Figure 2. Unresectable Hepatocellular Carcinoma Treatment Segment by Application in 2021
Figure 3. Global Unresectable Hepatocellular Carcinoma Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Unresectable Hepatocellular Carcinoma Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Unresectable Hepatocellular Carcinoma Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Unresectable Hepatocellular Carcinoma Treatment Revenue in 2021
Figure 8. By Treatment Method - Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 12. US Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 24. China Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Unresectable Hepatocellular Carcinoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bayer AG Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. BeiGene Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)